These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 35715969)

  • 41. Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation.
    De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Cacciola E; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Leone G; Barbui T;
    Ann Hematol; 2010 Feb; 89(2):141-6. PubMed ID: 19582452
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CALR versus JAK2 mutated essential thrombocythaemia - a report on 141 patients.
    Trifa AP; Popp RA; Cucuianu A; Bănescu C; Tevet M; Martin B; Murat M; Vesa SC; Dima D; Cândea M; Militaru MS; Pop IV
    Br J Haematol; 2015 Jan; 168(1):151-3. PubMed ID: 25103987
    [No Abstract]   [Full Text] [Related]  

  • 43. JAK2(V617F) positive early stage myeloproliferative disease (essential thrombocythemia) as the cause of portal vein thrombosis in two middle-aged women: therapeutic implications in view of the literature.
    Michiels JJ; Commandeur S; Hoogenboom GJ; Wegman JJ; Scholten L; van Rijssel RH; De Raeve H
    Ann Hematol; 2007 Nov; 86(11):793-800. PubMed ID: 17687555
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Rapid identification of heterozygous or homozygous JAK2(V617F) mutations in myeloproliferative neoplasms using melting curve analysis.
    Ho CL; Wu YY; Hung HM; Chang PY; Kao WY; Chen YC; Chao TY
    J Formos Med Assoc; 2012 Jan; 111(1):34-40. PubMed ID: 22333011
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Essential thrombocythemia - a predisponent factor for stroke.
    Batista TFP; Manuel PF; Correia AC
    Rev Assoc Med Bras (1992); 2019 Jul; 65(6):772-774. PubMed ID: 31340302
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
    Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
    Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impact of JAK2V617F mutation on thrombosis and myeloid transformation in essential thrombocythemia: a multivariate analysis by Cox regression in 141 patients.
    Chim CS; Sim JP; Chan CC; Kho BC; Chan JC; Wong LG; Law M; Liang R; Kwong YL
    Hematology; 2010 Aug; 15(4):187-92. PubMed ID: 20670476
    [TBL] [Abstract][Full Text] [Related]  

  • 48. JAK2 V617F-positive latent essential thrombocythemia and splanchnic vein thrombosis: the role of bone marrow biopsy for the diagnosis of myeloproliferative disease.
    Allegra A; Alonci A; Penna G; D'Angelo A; Rizzotti P; Granata A; Musolino C
    Acta Haematol; 2009; 121(4):218-20. PubMed ID: 19478480
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pathogenetic role of JAK2 V617F mutation in chronic myeloproliferative disorders.
    Hsu HC
    J Chin Med Assoc; 2007 Mar; 70(3):89-93. PubMed ID: 17389152
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Estimation of diagnosis and prognosis in ET by assessment of CALR and JAK2
    Saki N; Shirzad R; Rahim F; Saki Malehi A
    Clin Transl Oncol; 2017 Jul; 19(7):874-883. PubMed ID: 28205126
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Acquired JAK-2 V617F Mutational Analysis in Pakistani Patients with Essential Thrombocythemia.
    Sultan S; Irfan SM
    Asian Pac J Cancer Prev; 2015; 16(16):7327-30. PubMed ID: 26514532
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
    Tefferi A; Barbui T
    Am J Hematol; 2017 Jan; 92(1):94-108. PubMed ID: 27991718
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A sensitive and reliable semi-quantitative real-time PCR assay to detect JAK2 V617F in blood.
    Poodt J; Fijnheer R; Walsh IB; Hermans MH
    Hematol Oncol; 2006 Dec; 24(4):227-33. PubMed ID: 17006961
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL; Marton E; Plander M
    Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
    [TBL] [Abstract][Full Text] [Related]  

  • 55. TERT rs2736100 A>C SNP and JAK2 46/1 haplotype significantly contribute to the occurrence of JAK2 V617F and CALR mutated myeloproliferative neoplasms - a multicentric study on 529 patients.
    Trifa AP; Bănescu C; Tevet M; Bojan A; Dima D; Urian L; Török-Vistai T; Popov VM; Zdrenghea M; Petrov L; Vasilache A; Murat M; Georgescu D; Popescu M; Pătrinoiu O; Balea M; Costache R; Coleș E; Șaguna C; Berbec N; Vlădăreanu AM; Mihăilă RG; Bumbea H; Cucuianu A; Popp RA
    Br J Haematol; 2016 Jul; 174(2):218-26. PubMed ID: 27061303
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An unusual cause of cerebellar hemorrhage in a young patient: essential thrombocythemia.
    Adam R; Priglinger M; Harrington T; Gottlieb D; Krause M
    J Stroke Cerebrovasc Dis; 2014; 23(5):e373-4. PubMed ID: 24582788
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Repeat
    Kearney L; Lee Tokar L; Flynn C; Mykytiv V; Murphy K; Langabeer SE
    J Clin Pathol; 2020 Nov; 73(11):772. PubMed ID: 32646925
    [No Abstract]   [Full Text] [Related]  

  • 58. Chronic lymphocytic leukemia with essential thrombocythemia: asbestos exposure association?
    Chintapatla R; Battini R; Wiernik PH
    Clin Adv Hematol Oncol; 2012 Nov; 10(11):752-5. PubMed ID: 23271264
    [No Abstract]   [Full Text] [Related]  

  • 59. Transformed essential thrombocytosis with a JAK2 V617F mutation relapsing as JAK2 mutation-negative leukaemia after allogeneic stem cell transplantation.
    Au WY; Fung A; Lam KY; Lie AK; Liang R; Kwong YL
    Bone Marrow Transplant; 2006 Oct; 38(8):573-4. PubMed ID: 16953212
    [No Abstract]   [Full Text] [Related]  

  • 60. Evaluation of clinical and laboratory findings with JAK2 V617F mutation as an independent variable in essential thrombocytosis.
    Cetin G; Ozkan T; Turgut S; Ali Cikrikcioglu M; Cem Ar M; Ayer M; Unlu A; Celik SR; Sekin Y; Karatoprak C
    Mol Biol Rep; 2014 Oct; 41(10):6737-42. PubMed ID: 25012914
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.